Company: Dendreon Corp

A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease.

(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease.

A look at Nasdaq 10 most-active stocks at the close of trading:

A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Dendreon Corp. shares sank Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.

(Reuters) - Dendreon Crop <DNDN.O> said on Monday that first-quarter sales of its Provenge prostate cancer vaccine rose 6.5 percent over the prior quarter to $82 million, and that it still expects only modest sequential growth through the rest of 2012.

(Reuters) - Dendreon Crop <DNDN.O> said on Monday that first-quarter sales of its Provenge prostate cancer vaccine rose 6.5 percent over the prior quarter to $82 million, and that it still expects only modest quarter-over-quarter growth through the rest of 2012.

NEW YORK (Reuters) - More than 100 years after researchers first explored the potential to harness the body's immune system to fight cancer, the field's leading doctors see the concept finally proving itself on a large scale in the next year or two.

The wealthiest Americans have been in the spotlight over the past several years, for reasons ranging from public outrage over lavish lifestyles during the recession to executive bonuses in the midst of the financial crisis. The Occupy Wall Street movement was perhaps the most visible culmination of these concerns, broadly protesting against the divide between the majority of the U.S. population and the ultra-rich, referred to by the protesters as the “one percent.”

Chief executives at some of the biggest U.S. biotech and pharmaceutical companies are at the annual JPMorgan health care conference in San Francisco. Here's what some of them told  CNBC on Tuesday.

Dendreon reported a more than three-fold jump in fourth-quarter revenue of its prostate cancer vaccine Provenge, sending the biotechnology company's shares up as much as 50 percent on Thursday.

Stocks rebounded from earlier losses to finish narrowly mixed Thursday, with the S&P adding small gains to the New Year rally, ahead of a key government employment report. Stocks had been under pressure earlier in the session amid ongoing jitters over the European debt crisis and a decline in the euro to its lowest level since September 2010.